Close

Intercept Pharmaceuticals (ICPT) Price Target Raised to $493 at Wedbush

February 10, 2014 9:22 AM EST Send to a Friend
Wedbush maintained an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and raised its price target to $493.00 (from $449.00).

This article: 168 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login